Status:
COMPLETED
A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will assess the efficacy and safety of treatment with the combination Avastin (bevacizumab) 5mg/kg iv every 2 weeks, Xeloda (capecitabine) 1000 mg po b.i.d. on Days 1-14 of every 28-day cyc...
Eligibility Criteria
Inclusion
- Adult patients \>=18 years of age
- Locally advanced or metastatic colorectal cancer
- No previous treatment with chemotherapy for metastatic disease
- Measurable and/or evaluable lesions
Exclusion
- Radiotherapy within 4 weeks before study
- Untreated brain metastases or primary brain tumors
- Chronic, daily treatment with high-dose aspirin (\>325mg/day)
- Co-existing malignancies, or malignancies diagnosed within the last 5 years, with the exception of basal and squamous cell cancer, or cervical cancer in situ
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01159171
Start Date
January 1 2006
End Date
July 1 2010
Last Update
August 15 2014
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Aviano, Italy, 33081
2
Fano, Italy, 61032
3
Palermo, Italy, 90146
4
Rimini, Italy, 47900